Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

  04 October 2019

“We are thrilled to see these data, which demonstrate conclusively that the Accelerate PhenoTest™ BC kit positively impacts clinical outcomes across a diverse set of institutions and patient populations. The studies show an improvement in antibiotic use, a necessary factor for lowering the risk of multidrug-resistant infections and in preserving the patient’s vital functions, while also improving the hospital’s bottom line by reducing patient length of stay,” commented Dr. Romney Humphries, Chief Scientific Officer of Accelerate Diagnostics and former UCLA Section Chief for Clinical Microbiology.      

Authors: Accelerate Diagnostics
Smart Innovations  

Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market (max 5)
  • Global reach for funding / co-development / licensing
  • No costs (until year end 2019)

Festive Launch Database 19 Nov Symposium Dinner ‘Emerging Antimicrobials and Diagnostics in AMR 2019
Click to join the Symposium Dinner (to join the Symposium separate registration obligatory)

Display your technology >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!